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Immune Signals in
Parkinson’s Disease
The Jefferson Comprehensive Parkinson’s Disease
Center is one of the Parkinson’s Foundation’s
33 Centers of Excellence in the United States.
Its director, Richard Smeyne, PhD, professor
of neuroscience, and his research group are
examining the cell signaling and cascade of events
that leads to initiation of Parkinson’s disease (PD),
seeking important clues about ways to arrest
the condition’s progression. Mutation within the
Leucine-rich Repeat Kinase 2 (LRRK2) gene is
thought to underlie about 20 percent of all PD
cases. Two of the group’s recent studies suggest
that immune signaling from T-cells and B-cells
in the blood plays an unexpected and important
role in development of LRRK2-related PD.

that LRRK2 gene mutations affect inflammation
in mice. When they administered a compound
that mimics bacterial infections, they found that
only mice with LRRK2 mutations showed PD-like
effects in the brain. These effects included an
exacerbated brain inflammation that appeared
to arise from signals initiated in T- and B-cells
in the blood. This finding has the potential to
provide new targets for interfering with the
onset and progression of PD; it could also lead
to identification of blood-based biomarkers that
could be used as an “early warning” of PD.

In the second study, the researchers explored the
impact of substituting a normal mouse immune
system for one that has LRRK2 mutations. Would
The first of these studies explores neuroit “rescue” the mice from PD-like pathologies?
inflammation—one of the most common
They pursued this question in a creative way:
pathologies seen in PD—where specialized brain
generating a new strain of mice that contained
cells release chemicals that lead to neuron death.
LRRK2 mutations in all cells, but lacked an immune
To understand how this process starts and is
system; then using bone marrow transplantation
regulated, researchers led by senior postdoctoral
to give the mice a normal immune system. Thus,
fellow Elena Kozina, PhD, looked at the way
the mice had normal LRRK2 in their T- and B-cells,
but LRRK2 mutations in
other cells, including all
their brain cells. These
chimeric mice could then
be used to directly test the
This finding has the potential to provide
notion that signals from
the peripheral immune
new targets for interfering with the onset
system (the T- and B-cells)
and progression of PD; it could also lead to
prompted inflammation
in the brain—and that not
identification of blood-based biomarkers that
having LRRK2-mutated
could be used as an “early warning” of PD.
immune cells would
prevent PD-like symptoms.
“Our hypothesis proved
correct,” Dr. Smeyne says.
“Much of the mice’s brain-immune response was
normal; no neuron death was observed. This
important finding points to a new way to think
about how PD starts, and we are examining if this
‘crosstalk’ between the peripheral immune system
and the brain is at work in other forms of PD.” 
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One of the unique aspects of Thomas
Jefferson University is that students from
the Kanbar College of Design, Engineering
and Commerce have the opportunity
to interact and work with neurologist
Tsao-Wei Liang, MD, to develop novel and
practical devices to help patients with PD.

Through a summer work-study program,
design students have been invited to the
Movement Disorders clinic to evaluate the
daily struggles of patients, return to the studio
and then brainstorm to create and develop
prototypes that have the potential to improve
the quality of life of persons with Parkinson’s.

Applying New Knowledge
for Parkinson’s Patients
Beyond its leading program of basic and translational research into the biological
mechanisms underlying Parkinson’s disease, the Jefferson Comprehensive
Parkinson’s Disease Center leverages the University’s broad range of capacities
in clinical and applied research. For example, the Center’s active clinical research
and experimental therapeutics program runs clinical trials that range from
evaluating novel delivery systems for levodopa and testing adjunct medications
for motor complications to assessing new systems for deep brain stimulation
therapy and gauging the impact of nutritional support for PD patients.
On the applied end of the research spectrum, Jefferson design students work
with Tsao-Wei Liang, MD, associate professor of neurology, to develop novel
and practical devices to help patients. The students observe and learn about
the daily struggles of patients in the Center’s Movement Disorders clinic;
then they return to the design studio to conceive and develop prototypes of
products with real potential to improve quality of life of those patients.
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